

**Title: Patients with COVID-19 Infection and Stroke have Higher than Expected Mortality,
Regardless of the Primary Presentation**

Short title: COVID-19 Infection and Stroke

Jintong Liu, BS¹, Eric Fu, MS¹, Riley Gillette, MPH¹, Max Wohlauer, MD^{1*}

¹University of Colorado School of Medicine,

*Correspondence: max.wohlauer@cuanschutz.edu

12631 E. 17th Avenue, Room 5411

Aurora, CO 80045

Total Word Count: 4281

1 **Abstract**

2 **Background**

3 COVID-19 infection is associated with thrombotic events; however, this phenomenon is poorly
4 understood. Few studies have reported the association between COVID-19 and stroke in the
5 hospital setting.

6

7 **Methods**

8 We retrospectively reviewed and characterized all patients who presented to a single, quaternary
9 medical center between March and December 2020 (N=603). COVID-19 positive patients who
10 developed ischemic or hemorrhagic stroke were included in the analysis (N=66). This cohort was
11 compared with patients who were COVID-19 negative at the time of stroke presentation in the
12 same period (N=537). Statistical significance was evaluated using Pearson's Chi squared test
13 with Yates' continuity correction and linear model ANOVA.

14

15 **Results**

16 Sixty-six patients had COVID-19 and Stroke. Of these patients, 22 (33.4%) patients initially
17 presented with stroke and 44 (66.7%) initially presented with COVID-19. Patients who presented
18 with COVID-19 and had a stroke during their hospitalization (COVID-first) had worse outcomes
19 than patients presenting to the hospital with stroke whose COVID test became positive later in
20 the hospitalization (stroke-first). Patients who presented with COVID-19 and had a stroke during
21 their hospitalization had an increased rate of acute renal failure (48.9% vs 19.0%, p=0.021) and
22 need for ventilation (60.0% vs 28.6%, p=0.017). Further, in the COVID-first cohort, the use of

23 heparin prior to the stroke event was not associated with mortality or type of stroke (ischemic or
24 hemorrhagic).

25

26 **Conclusion**

27 In the early pandemic, patients with COVID-19 infection and stroke had a higher mortality rate
28 compared to COVID-19 negative patients with stroke. Among patients with both COVID-19 and
29 stroke, patients presenting with COVID-19 first had worse outcomes than patients presenting
30 with stroke first. The use of heparin prior to the stroke event was not associated with mortality or
31 type of stroke.

32

33 **Key words:**

34 COVID-19

35 Stroke

36

37 **Non-standard Abbreviations and Acronyms**

38 chronic kidney disease (CKD)

39 angiotensin-converting enzyme 2 (ACE2)

40

41

42

43

44

45

46 **Introduction**

47 Over 6.9 million people have died from COVID-19 worldwide and hundreds of millions more
48 have suffered from SARS-CoV-2 associated illness.¹ While most symptoms involve the
49 respiratory tract, neurologic symptoms such as altered consciousness, seizures, stroke, and
50 sensory deficits have been extensively described.² Stroke incidence in COVID-19 patients
51 ranges between 0.1 to 6.9% of hospitalized cases.^{3,4}

52
53 COVID-19 is associated with a hypercoagulable state and resulting thromboembolic events,
54 including deep vein thrombosis, pulmonary embolism, and stroke.⁴⁻⁷ Several mechanisms have
55 been proposed including endothelial injury, inflammation, complement activation, and
56 deactivation of antithrombotic pathways.⁸ An interesting model, based off postmortem studies
57 and these mechanisms, postulates that injury to the lung tri-compartment (pulmonary artery,
58 bronchial artery, and alveolus) leads to pulmonary vein thrombosis and subsequent large vessel
59 occlusion (LVO)⁹. In terms of demographics, COVID-19 patients who suffered strokes are also
60 demographically different from traditional stroke patients. They are typically younger, more
61 often without previous vascular risk factors, more likely to be male, and more likely to
62 experience large vessel occlusions.^{3,5,10}

63
64 Despite the large number of studies on stroke and COVID-19 that have been published, a causal
65 relationship between SARS-CoV-2 and stroke has yet to be established.³ Moreover, there is a
66 notable gap in research concerning hemorrhagic stroke within the context of SARS-CoV-2
67 infection, despite documented instances of hemorrhagic complications.^{4,5} In addition to reporting
68 occurrence and outcome, one way to explore possible correlations is by differentiating the

69 chronologic sequence of the presenting symptoms. Our study separates stroke patient outcomes
70 through patients' primary presentation, whether they presented with COVID-19 or stroke first.
71 Furthermore, we explored the relationship between timing of anticoagulation on outcomes,
72 which has not been described previously.

73

74 **Methods**

75 We conducted a retrospective study of 603 consecutive patients who presented with stroke in a
76 quaternary medical center between March 2020 and December 2020. Sixty-six patients who
77 were COVID-19 positive and 537 patients who were COVID-19 negative at the time of ischemic
78 or hemorrhagic stroke presentation were included. Characteristics and comorbidities were
79 identified and compared between two groups using Pearson's Chi squared test with Yates'
80 continuity correction and linear model ANOVA. Missing data such as race and sex were not
81 included in analysis. Comparisons stratified by stroke types (ischemic or hemorrhagic) and
82 mortality rates were also performed. Within the 66 patients who were COVID-19 positive at the
83 time of ischemic or hemorrhagic stroke presentation, we further stratified by their primary
84 presentation, whether patients presented with COVID-19 first and developed a stroke during
85 their hospitalization (N=45) (stroke-first) or whether stroke was the initial presenting symptom
86 of COVID-19 (COVID-first) (N=21). Characteristics, comorbidities, and outcomes were
87 compared between two groups. A multivariable logistic regression model was used with the
88 presence or absence of postoperative death as the dependent variable, COVID-19 and stroke
89 presentation, and comorbidities diabetes mellitus and chronic kidney disease (CKD) as
90 independent variables based off significance in univariate analyses. In addition, we identified
91 causes of death by systems for those who were COVID-19 positive at the time of stroke

92 presentation. Lastly, for the COVID-first cohort (N=45), we distinguished those who received
93 prophylaxis or therapeutic heparin from those who did not prior to the onset of stroke. The types
94 of stroke and mortality rate were then compared with Pearson's Chi-squared test with Yates'
95 continuity correction. Statistical significance was defined as $p < 0.05$. Analyses were done using
96 R (version 4.2.0, R Foundation for Statistical Computing, Vienna, Austria).

97

98 The case report form was developed by a working group of the Vascular Surgery COVID-19
99 Collaborative (VASCC).¹¹ The VASCC was established on March 2, 2020, to study the impact
100 of the ongoing COVID-19 pandemic on vascular surgical care. STROBE guidelines for
101 observational studies were followed.

102

103 **Results**

104 The mean age for all patients was 64.4 years old, and it was similar between both cohorts (Table
105 1). More patients identified as Hispanic in the COVID & Stroke cohort than patients in the
106 Stroke Only cohort (40.9% vs 11.4%, $p < 0.001$). The male and female distribution was similar
107 between the two cohorts ($p = 0.200$). Prevalence of diabetes mellitus and chronic kidney disease
108 were higher in the COVID & Stroke cohort than in the Stroke Only cohort ($p < 0.001$). Ischemic
109 stroke was more prevalent than hemorrhagic stroke in all patients and in both cohorts. Mortality
110 was significantly higher in the COVID & Stroke cohort (patients with COVID who developed a
111 stroke) than in the Stroke Only cohort (37.9% vs 17.3%, $p < 0.001$).

112

113 Stratified based on the stroke type (hemorrhagic or ischemic), similar results were found
114 (Supplemental Tables 1 and 2). However, for patients presented with hemorrhagic stroke, the

115 mortality rates were not statistically significant between the COVID & Stroke cohort and the
116 Stroke Only cohort (40.9% vs 26.4%, p=0.249). When modeled in a multivariable logistic
117 regression framework, Stroke and COVID-19 presentation (OR: 0.41, 95% C.I. (0.23, 0.73),
118 p=0.002) and CKD (2.36, (1.12-4.82), p = 0.02) were significantly associated with postoperative
119 death, diabetes mellitus did not have a significant association (1.15, (0.73,1.79), p=0.528).
120 Patients who presented with stroke only were less likely to experience postoperative death
121 compared to those with both stroke and COVID-19. Patients with CKD were more likely to
122 experience postoperative death compared to non-CKD patients. In terms of revascularization, out
123 of 44 patients with ischemic stroke and COVID-19, only one patient received mechanical
124 thrombectomy and only three patients received IV thrombolysis (2.3% and 6.8% respectively).
125
126 When stratified by primary presentation (COVID or Stroke) within the COVID & Stroke cohort,
127 demographic characteristics and comorbidities were not significantly different between the two
128 groups (Table 2). Type of strokes and mortality rates were also not significantly different
129 between two groups. Patients with COVID-19 as the primary presentation were associated with
130 worse outcomes including increased acute renal failure and need for ventilation rates when
131 compared to patients presented with stroke first (48.9% versus 19.0%, p=0.021 and 60.0% versus
132 28.6%, p=0.017, respectively).
133
134 We also characterized causes of death in patients who were COVID-19 positive at the time of
135 stroke presentation (the COVID & Stroke cohort) (Table 3). Among all patients, neurological
136 causes of death were most common, followed by pulmonary causes.
137

138 In the COVID-first cohort (N=45), the use of heparin prior to the stroke event was not associated
139 with type of stroke or mortality (Table 4). Among the 29 patients who received heparin, 13
140 developed hemorrhagic stroke, and 16 developed ischemic stroke, which was not significantly
141 different from those who did not receive heparin (p=0.321). Mortality rate was 41.4% in those
142 who received heparin while 37.5% in those who did not receive heparin (p=1.000).

143

144 **Discussion**

145 In this retrospective cohort study, we found significant differences in the demographics of the
146 cohort who had a stroke versus those who had both a stroke and COVID-19 in terms of the
147 presence of diabetes, CKD, and race. We also found a significant difference in mortality and
148 morbidity. Additionally, we looked specifically at those with hemorrhagic stroke, as opposed to
149 ischemic stroke, and did not find a correlation with heparin use in our cohort in contrast to
150 previous studies.

151

152 **Stroke Overall**

153 In terms of both ischemic and hemorrhagic stroke, our key findings include a greater prevalence
154 of diabetes, CKD, and Hispanic ethnicity in those with COVID-19 infection and stroke than
155 those with only a stroke, higher mortality in those with both, and worse outcomes for those
156 presented with COVID-19 first then stroke as opposed to stroke first then COVID-19.

157

158 It has been widely observed that diabetes and CKD are both risk factors associated with
159 increased COVID-19 infection rates and the severity.^{12,13} For our cohort, diabetes mellitus (27%
160 vs 56%, p<0.001) and CKD (4.5% vs 20%, p<0.001) were both significantly more prevalent in

161 those who had COVID and stroke than those who presented only with stroke. Not only are
162 patients with these comorbidities more likely to be infected by SARS-CoV2, but they could also
163 be more likely to suffer stroke while infected.

164

165 Additionally, there is a significant difference in the racial makeup of those who suffered only a
166 stroke (n=537) versus those who had both COVID-19 and stroke (n=66, p<0.001). This contrasts
167 with no significant difference found between those who had COVID-19 first then stroke versus
168 having stroke first then COVID-19. This significant difference aligns with general COVID-19
169 trends where the infection disproportionately affects those in the minority.¹⁴ We observed that
170 those who identify as Hispanic were a significantly greater percentage of the overall COVID-19
171 and stroke patient population than stroke only (41% vs 13%).

172

173 In terms of mortality, our findings revealed that those with COVID-19 and stroke during the
174 same hospital stay exhibited a higher death rate than those who suffered from a stroke only (38%
175 vs 17%, p<0.001) in the early stages of pandemic. This builds upon earlier research indicating
176 elevated mortality in COVID-19 patients with stroke compared to those without,¹⁵ as well as an
177 increased risk of severe disability and mortality when compared to propensity-matched non-
178 COVID-19 stroke patients.^{16,17} Our clinical observations align with this conclusion, suggesting
179 that a higher disease burden correlates with increased mortality, particularly in diseases with
180 inherently high mortality rates. Furthermore, even within the same disease, more severe
181 infections were associated with a higher incidence of stroke.¹⁵

182

183 Interestingly, patients who presented with COVID-19 and had a stroke during their
184 hospitalization (COVID-first) had worse outcomes than patients presenting to the hospital with
185 stroke whose COVID-19 test became positive later in the hospitalization (stroke first). Those
186 who were admitted with symptoms of COVID-19 and endured a stroke during their
187 hospitalization were more likely to have acute renal failure (49% vs 19%, $p=0.021$) and need
188 ventilation (60% vs 29%, $p=0.017$). This could reflect the differences in the severity of the
189 COVID-19 infection in the two groups. For patients with stroke first in this study, they were
190 more likely to have an asymptomatic COVID-19 infection that was not severe enough to have
191 been tested. For those with COVID-19 first, they were likely hospitalized with COVID-19
192 pneumonia and needed ventilation and were also more likely to experience acute renal failure, a
193 common morbidity of COVID-19.¹⁸

194

195 **Hemorrhagic Stroke**

196 Despite COVID-19 being mostly characterized as a hypercoagulable state, bleeding
197 complications such as increased morbidity/mortality post-stroke revascularization and
198 hemorrhagic strokes have been reported.^{4,6,19} Previous studies found that while inherent risk of
199 hemorrhagic stroke low, overall risk is increased in the setting of full-dose anticoagulation use
200 for thromboembolism prevention as part of COVID-19 management.²⁰ Thus, our study strived to
201 delineate between ischemic and hemorrhagic stroke, separate outcome by heparin use, and
202 compare comorbidities within each type of stroke between those who had stroke only versus
203 those who had both COVID-19 and stroke.

204

205 Among patients with hemorrhagic stroke, hyperlipidemia was more likely in those who had both
206 stroke and COVID-19 than those who only had a stroke (p=0.046). While previous studies found
207 that hyperlipidemia is not significantly associated with all-cause mortality in COVID-19 patients,
208 it in combination with COVID-19 may specifically predispose patients to hemorrhagic stroke.²¹
209 Second, in contrast with previous studies, we did not find hemorrhagic stroke to be more
210 common in patients with pre-existing hypertension and diabetes mellitus prior to COVID-19
211 infection.²² Third, in the COVID-first cohort (N=45), the use of heparin prior to the stroke event
212 showed no significant correlation with mortality (p=1.000) or type of stroke (p=0.321). This
213 outcome is surprising given anticoagulation is a known risk of hemorrhage.²³ When compared to
214 findings from a previous a multinational study, our research revealed a higher prevalence of
215 hemorrhagic strokes (33.3% versus 21.1%).²⁴ Contrary to expectations, our results suggest that
216 the use of heparin prior to a stroke does not seem to contribute to the elevated incidence of
217 hemorrhagic strokes. This intriguing observation prompts the need for further exploration and
218 investigation.

219

220 Hemorrhagic stroke in patients with COVID-19 has not been heavily studied and mechanisms
221 are still being elucidated. In combining our findings with those of others, several possible
222 mechanisms begin to emerge. COVID-19 disproportionately affects those with underlying
223 hypertension and diabetes and further elevates blood pressure through ACE2 dysregulation and
224 endothelial dysfunction.^{23,25} Furthermore, anticoagulant use has become wide-spread in COVID-
225 19 treatment.^{23,25} Dysregulated fibrinolysis could be another co-existing or separate mechanism.

226 ²⁰ As such, patient risk factors should be considered when starting anticoagulation therapy.^{20,25}

227

228 **Limitations**

229 Our study is limited by data from a single center and the retrospective nature of the study. The
230 study is a snapshot in time, focusing on the 66 patients with both COVID-19 and stroke who
231 presented from during the initial waves of COVID-19 (March to December of 2020) and was
232 prior to the introduction of vaccines. This may limit the generalizability of the study. Second, our
233 examination on heparin-use and its resultant morbidity and mortality was done retrospectively.

234

235 Additionally, our ability to conduct statistical analyses was limited due to the small number of
236 patients undergoing revascularization. Only one out of the 44 patients with ischemic stroke and
237 COVID-19 underwent mechanical thrombectomy, while just three received IV thrombolysis
238 (2.3% and 6.8%, respectively). These figures are notably lower when compared to a previous
239 multinational study, where 7.4% of patients underwent mechanical thrombectomy and 13.6%
240 received IV thrombolysis.²⁴ The majority of patients in our study faced challenges in receiving
241 revascularization, either due to their unstable condition, being outside the optimal
242 revascularization window, or lacking indications for the procedure. Despite the absence of
243 formal analysis in our study, a recent international multicenter retrospective cohort study
244 suggested that patients with COVID-19 who underwent revascularization experienced worse
245 outcomes than their counterparts without COVID-19 who underwent similar interventions.¹⁹

246

247 In summary, our study retrospectively examined patients at a tertiary medical center during the
248 initial wave of COVID-19 and found several previously less reported trends among stroke
249 patients. First, patients with COVID-19 infection and stroke had a higher mortality rate than
250 patients with only stroke. Second, among patients with both COVID-19 and stroke, patients

251 presenting with COVID-19 first had worse outcomes, including higher frequency of acute renal
252 failure and need for ventilation, than patients presenting with stroke first. Third, contrary to
253 previous studies, the use of heparin prior to the stroke event was not associated with mortality or
254 type of stroke.

255

256 **Acknowledgments**

257 We would like to thank the Medical Student Summer Research Program (MSRP) and
258 Department of Surgery at the University of Colorado School of Medicine for providing time and
259 support to perform this project. We would like to thank the Division of Neurology at the
260 University of Colorado School of Medicine for their collaboration, and for providing valuable
261 input and expertise.

262

263 **Sources of Funding**

264 None.

265

266 **Disclosures**

267 No financial conflicts to disclose.

268

269

270

271

272

273

274 **References:**

- 275 1. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at
276 Johns Hopkins University (JHU). <https://coronavirus.jhu.edu/map.html>. 2023. Accessed
277 September 3rd.
- 278 2. Harapan BN, Yoo HJ. Neurological symptoms, manifestations, and complications
279 associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and
280 coronavirus disease 19 (COVID-19). *J Neurol*. 2021;268:3059-3071. doi:
281 10.1007/s00415-021-10406-y
- 282 3. Sagris D, Papanikolaou A, Kvernland A, Korompoki E, Frontera JA, Troxel AB,
283 Gavriatopoulou M, Milionis H, Lip GYH, Michel P, et al. COVID-19 and ischemic
284 stroke. *Eur J Neurol*. 2021;28:3826-3836. doi: 10.1111/ene.15008
- 285 4. Mbonde AA, O'Carroll CB, Grill MF, Zhang N, Butterfield R, Demaerschalk BM. Stroke
286 Features, Risk Factors, and Pathophysiology in SARS-CoV-2-Infected Patients. *Mayo*
287 *Clin Proc Innov Qual Outcomes*. 2022;6:156-165. doi: 10.1016/j.mayocpiqo.2022.01.003
- 288 5. Luo W, Liu X, Bao K, Huang C. Ischemic stroke associated with COVID-19: a
289 systematic review and meta-analysis. *J Neurol*. 2022;269:1731-1740. doi:
290 10.1007/s00415-021-10837-7
- 291 6. Amiri HA, Razavi AS, Tabrizi N, Cheraghmakani H, Baghbanian SM, Sedaghat-Chaijan
292 M, Zarvani A, Ghazaeian M, Hosseinnataj A. The Effects of COVID-19 on Patients with
293 Acute Ischemic and Hemorrhagic Stroke. *J Stroke Cerebrovasc Dis*. 2022;31:106512.
294 doi: 10.1016/j.jstrokecerebrovasdis.2022.106512

- 295 7. Alahyari S, Moradi M, Rajaeinejad M, Jalaeikhoo H. Post-COVID-19 hematologic
296 complications: a systematic review. *Expert Rev Hematol.* 2022;15:539-546. doi:
297 10.1080/17474086.2022.2080051
- 298 8. Shibeeb S, Ahmad MN. Thrombotic and Hypercoagulability Complications of COVID-
299 19: An Update. *J Blood Med.* 2021;12:785-793. doi: 10.2147/jbm.S316014
- 300 9. Meaney JFM, O'Donnell JS, Bridgewood C, Harbison J, McGonagle D. Perspective: The
301 Case for Acute Large Vessel Ischemic Stroke in COVID-19 Originating Within
302 Thrombosed Pulmonary Venules. *Stroke.* 2022;53:2411-2419. doi:
303 10.1161/strokeaha.121.038056
- 304 10. Jabbour P, Dmytriw AA, Sweid A, Piotin M, Bekelis K, Sourour N, Raz E, Linfante I,
305 Dabus G, Kole M, et al. Characteristics of a COVID-19 Cohort With Large Vessel
306 Occlusion: A Multicenter International Study. *Neurosurgery.* 2022;90:725-733. doi:
307 10.1227/neu.0000000000001902
- 308 11. Mouawad NJ, Cuff RF, Hultgren R, Chuen J, Galeazzi E, Wohlauer M. The Vascular
309 Surgery COVID-19 Collaborative (VASCC). *J Vasc Surg.* 2020;72:379-380. doi:
310 10.1016/j.jvs.2020.04.463
- 311 12. Singh AK, Gupta R, Ghosh A, Misra A. Diabetes in COVID-19: Prevalence,
312 pathophysiology, prognosis and practical considerations. *Diabetes Metab Syndr.*
313 2020;14:303-310. doi: 10.1016/j.dsx.2020.04.004
- 314 13. Gansevoort RT, Hilbrands LB. CKD is a key risk factor for COVID-19 mortality. *Nat*
315 *Rev Nephrol.* 2020;16:705-706. doi: 10.1038/s41581-020-00349-4

- 316 14. Golestaneh L, Neugarten J, Fisher M, Billett HH, Gil MR, Johns T, Yunes M, Mokrzycki
317 MH, Coco M, Norris KC, et al. The association of race and COVID-19 mortality.
318 *EClinicalMedicine*. 2020;25:100455. doi: 10.1016/j.eclinm.2020.100455
- 319 15. Ahmad SJ, Feigen CM, Vazquez JP, Kobets AJ, Altschul DJ. Neurological Sequelae of
320 COVID-19. *J Integr Neurosci*. 2022;21:77. doi: 10.31083/j.jin2103077
- 321 16. Ntaios G, Michel P, Georgiopoulos G, Guo Y, Li W, Xiong J, Calleja P, Ostos F,
322 González-Ortega G, Fuentes B, et al. Characteristics and Outcomes in Patients With
323 COVID-19 and Acute Ischemic Stroke: The Global COVID-19 Stroke Registry. *Stroke*.
324 2020;51:e254-e258. doi: 10.1161/strokeaha.120.031208
- 325 17. Yassin A, Ghzawi A, Al-Mistarehi AH, El-Salem K, A YB, A MS, BenhadjDahman N,
326 AlAdamat N, Jemel A, Negida A, et al. Mortality rate and biomarker expression within
327 COVID-19 patients who develop acute ischemic stroke: a systematic review and meta-
328 analysis. *Future Sci OA*. 2021;7:Fso713. doi: 10.2144/fsoa-2021-0036
- 329 18. Yang X, Jin Y, Li R, Zhang Z, Sun R, Chen D. Prevalence and impact of acute renal
330 impairment on COVID-19: a systematic review and meta-analysis. *Crit Care*.
331 2020;24:356. doi: 10.1186/s13054-020-03065-4
- 332 19. Strambo D, Marto JP, Ntaios G, Nguyen TN, Michel P. Effect of Asymptomatic and
333 Symptomatic COVID-19 on Acute Ischemic Stroke Revascularization Outcomes. *Stroke*.
334 2024;55:78-88. doi: 10.1161/strokeaha.123.043899
- 335 20. Kvernland A, Kumar A, Yaghi S, Raz E, Frontera J, Lewis A, Czeisler B, Kahn DE,
336 Zhou T, Ishida K, et al. Anticoagulation use and Hemorrhagic Stroke in SARS-CoV-2
337 Patients Treated at a New York Healthcare System. *Neurocrit Care*. 2021;34:748-759.
338 doi: 10.1007/s12028-020-01077-0

- 339 21. Wu B, Zhou JH, Wang WX, Yang HL, Xia M, Zhang BH, She ZG, Li HL. Association
340 Analysis of Hyperlipidemia with the 28-Day All-Cause Mortality of COVID-19 in
341 Hospitalized Patients. *Chin Med Sci J*. 2021;36:17-26. doi: 10.24920/003866
- 342 22. Wang H, Tang X, Fan H, Luo Y, Song Y, Xu Y, Chen Y. Potential mechanisms of
343 hemorrhagic stroke in elderly COVID-19 patients. *Aging (Albany N Y)*. 2020;12:10022-
344 10034. doi: 10.18632/aging.103335
- 345 23. Flaherty ML, Kissela B, Woo D, Kleindorfer D, Alwell K, Sekar P, Moomaw CJ,
346 Haverbusch M, Broderick JP. The increasing incidence of anticoagulant-associated
347 intracerebral hemorrhage. *Neurology*. 2007;68:116-121. doi:
348 10.1212/01.wnl.0000250340.05202.8b
- 349 24. Shahjouei S, Tsivgoulis G, Farahmand G, Koza E, Mowla A, Vafaei Sadr A, Kia A,
350 Vaghefi Far A, Mondello S, Cernigliaro A, et al. SARS-CoV-2 and Stroke
351 Characteristics: A Report From the Multinational COVID-19 Stroke Study Group.
352 *Stroke*. 2021;52:e117-e130. doi: 10.1161/strokeaha.120.032927
- 353 25. Dogra S, Jain R, Cao M, Bilaloglu S, Zagzag D, Hochman S, Lewis A, Melmed K,
354 Hochman K, Horwitz L, et al. Hemorrhagic stroke and anticoagulation in COVID-19. *J*
355 *Stroke Cerebrovasc Dis*. 2020;29:104984. doi:
356 10.1016/j.jstrokecerebrovasdis.2020.104984

357

358

359

360

361

Table 1. Demographic Characteristics, Comorbidities, and Outcomes for all Patients				
Variables	All Patients (N=603)	COVID & Stroke (N=66)	Stroke Only (N=537)	p values
Mean Age (SD)	64.40 (17.90)	62.11 (14.97)	64.68 (18.22)	0.270
Race				<0.001
Native American	4 (0.7%)	0 (0.0%)	4 (0.7%)	
Asian or Pacific Islander	24 (4.0%)	5 (7.6%)	19 (3.5%)	
Black, Non-Hispanic	98 (16.3%)	4 (6.1%)	94 (17.5%)	
Hispanic	88 (14.6%)	27 (40.9%)	61 (11.4%)	
White, Non-Hispanic	290 (48.1%)	26 (39.4%)	264 (49.2%)	
Unknown/Other	99 (16.4%)	4 (6.1%)	95 (17.7%)	
Sex				0.200
Female	240 (39.8%)	25 (37.9%)	215 (40.0%)	
Male	282 (46.8%)	41 (62.1%)	241 (44.9%)	
Unknown/Other	81 (13.4%)	0 (0.0%)	81 (15.1%)	
Comorbidities				
Diabetes Mellitus	182 (30.2%)	37 (56.1%)	145 (27.0%)	<0.001
Coronary Artery Disease	66 (10.9%)	6 (9.1%)	60 (11.2%)	0.762
Congestive Heart Failure	43 (7.1%)	7 (10.6%)	36 (6.7%)	0.363
History of Stroke	112 (18.6%)	11 (16.7%)	101 (18.8%)	0.799
Transient Ischemic Attack	25 (4.1%)	6 (9.1%)	19 (3.5%)	0.071
Hyperlipidemia	184 (30.5%)	24 (36.4%)	160 (29.8%)	0.341
Hypertension	371 (61.5%)	45 (68.2%)	326 (60.7%)	0.297
Atrial Fibrillation	57 (9.5%)	5 (7.6%)	52 (9.7%)	0.742
Chronic Kidney Disease	37 (6.1%)	13 (19.7%)	24 (4.5%)	<0.001
Obesity (BMI > 30 kg/m ²)	21 (3.5%)	3 (4.5%)	18 (3.4%)	0.886
Tobacco Use	130 (21.6%)	10 (15.2%)	120 (22.3%)	0.237
Stroke Type				0.331
Hemorrhagic	166 (27.5%)	22 (33.3%)	144 (26.8%)	
Ischemic	437 (72.5%)	44 (66.7%)	393 (73.2%)	
Death	118 (19.6%)	25 (37.9%)	93 (17.3%)	<0.001

363 Table 1. Demographic characteristics, comorbidities, and outcomes for all patients presented
364 with stroke to a tertiary medical center between March 2020 and December 2020. COVID &
365 Stroke cohort included patients who were COVID-19 positive at the time of stroke presentation,
366 while Stroke Only cohort included patients who were COVID-19 negative. SD = standard
367 deviation. p values compared COVID & Stroke cohort and Stroke Only cohort.

Table 2. Demographic Characteristics, Comorbidities, and Outcomes for Patients with COVID-19 and Stroke			
Variables	COVID-First (N=45)	Stroke-First (N=21)	p values
Mean Age (SD)	62.73 (12.51)	60.76 (19.52)	0.622
Race			0.165
Native American	0 (0.0%)	0 (0.0%)	
Asian or Pacific Islander	3 (6.7%)	2 (9.5%)	
Black, Non-Hispanic	2 (4.4%)	2 (9.5%)	
Hispanic	22 (48.9%)	5 (23.8%)	
White, Non-Hispanic	17 (37.8%)	9 (42.9%)	
Unknown/Other	1 (2.2%)	3 (14.3%)	
Sex			0.166
Female	14 (31.1%)	11 (52.4%)	
Male	31 (68.9%)	10 (47.6%)	
Comorbidities			
Diabetes Mellitus	27 (60.0%)	10 (47.6%)	0.498
Coronary Artery Disease	2 (4.4%)	4 (19.0%)	0.144
Congestive Heart Failure	6 (13.3%)	1 (4.8%)	0.532
History of Stroke	7 (15.6%)	4 (19.0%)	1.000
Transient Ischemic Attack	3 (6.7%)	3 (14.3%)	0.587
Hyperlipidemia	15 (33.3%)	9 (42.9%)	0.635
Hypertension	29 (64.4%)	16 (76.2%)	0.503
Atrial Fibrillation	3 (6.7%)	2 (9.5%)	1.000
Chronic Kidney Disease	9 (20.0%)	4 (19.0%)	1.000
Obesity (BMI > 30 kg/m ²)	3 (6.7%)	0 (0.0%)	0.564
Tobacco Use	8 (17.8%)	2 (9.5%)	0.615
Days Between COVID and Stroke	19.30 (16.73)	1.00 (1.76)	
Stroke Type			0.400
Hemorrhagic	17 (37.8%)	5 (23.8%)	
Ischemic	28 (62.2%)	16 (76.2%)	
Outcomes			
Acute Renal Failure	22 (48.9%)	4 (19.0%)	0.021
Ventilation	27 (60.0%)	6 (28.6%)	0.017
Tracheostomy	5 (11.1%)	0 (0.0%)	0.112
ECMO	4 (8.9%)	0 (0.0%)	0.159
Myocardial infarction	5 (11.1%)	0 (0.0%)	0.112
Death	18 (40.0%)	7 (33.3%)	0.804

369 Table 2. Demographic characteristics, comorbidities, and outcomes for patients who were
 370 COVID-19 positive when presented with stroke to a tertiary medical center between March 2020
 371 and December 2020. COVID-first group included patients who were diagnosed with COVID-19
 372 prior to stroke presentation, while Stroke-first group included patients who were diagnosed with
 373 COVID-19 after stroke presentation. SD = standard deviation.
 374

Table 3. Causes of Death by Systems in the COVID & Stroke Cohort			
	COVID-First	Stroke-First	Total
Pulmonary	7	2	9
Neurological	7	4	11
Multi-organs	3	0	3
Unknown	1	1	2

375 Table 3. Causes of death by system in patients who were COVID-19 positive at the time of
 376 stroke presentation.
 377

Table 4. Stroke Types and Mortality for Patients Received Heparin or Not Prior to Stroke Onset			
	Received Heparin	Did not Receive Heparin	p values
Total	29	16	
Stroke Type			0.321
Hemorrhagic	13 (44%)	4 (25%)	
Ischemic	16 (55.2%)	12 (75%)	
Death	12 (41.4%)	6 (37.5)	1.000

378 Table 4. Stroke types and mortality for patients presented diagnosed with COVID-19 prior to
 379 stroke presentation to a tertiary medical center between March 2020 and December 2020,
 380 stratified by whether received heparin or not prior to stroke onset.
 381
 382

383 **Supplemental Materials**

384 **Tables S1-S2**